Validation of a stability-indicating RP-LC method for the assessment of recombinant human interleukin-11 and its correlation with bioassay

Anal Sci. 2012;28(3):215-20. doi: 10.2116/analsci.28.215.

Abstract

A stability-indicating reversed-phase liquid chromatography (RP-LC) method was validated for the assessment of recombinant human interleukin-11 (rhIL-11), based on the ICH guidelines. The method was carried out on a Jupiter C(4) column (250 mm × 4.6 mm i.d.), maintained at 25°C. The mobile phase A consisted of 0.1% trifluoroacetic acid (TFA) and the mobile phase B was acetonitrile with 0.1% TFA, run at a flow rate of 1 mL/min, and using a photodiode array (PDA) detection at 214 nm. Separation was obtained with a retention time of 27.6 min, and was linear over the concentration range of 1-200 µg/mL (r(2) = 0.9995). Specificity was established in degradation studies, which also showed that there was no interference of the excipients. The accuracy was 100.22% with bias lower than 1.25%. Moreover, the in vitro cytotoxicity test of the degraded products showed non-significant differences (p > 0.05). The method was applied to the assessment of rhIL-11 and related proteins in biopharmaceutical dosage forms, and the results were correlated to those of a bioassay.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Animals
  • Biological Assay*
  • Cell Line
  • Cell Proliferation / drug effects
  • Chromatography, Reverse-Phase / methods*
  • Humans
  • Interleukin-11 / analysis
  • Interleukin-11 / isolation & purification*
  • Interleukin-11 / pharmacology*
  • Interleukin-11 / toxicity
  • Limit of Detection
  • Quality Control
  • Recombinant Proteins / analysis
  • Recombinant Proteins / isolation & purification*
  • Recombinant Proteins / pharmacology*
  • Recombinant Proteins / toxicity

Substances

  • Interleukin-11
  • Recombinant Proteins